



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 20 November 2000



21 JUL 97 E290164-1 D02656
P01/7700 25.00 - 9715214.4

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

18 JUL 1997

RECEIVED BY HAND

1. Your reference

P12266 r6/tm

2. Patent application number **9715214.4**

18 JUL 1997

(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)Finnfeeds International Ltd
PO Box 777
Marlborough
Wiltshire SN8 1XN

6465413002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Use of an enzyme for manufacturing an agent for controlling bacterial infection

David Lethem

Hoffmann Eitle
European Patent Attorneys
Sardinia House
52 Lincoln's Inn Fields
LONDON WC2A 3LZ

07156466001

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

Patents ADP number (if you know it)

Priority application number

Date of filing

(if you know it)

(day / month / year)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or of each application number

Number of earlier application

Date of filing

(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Yes

8. Is a statement of inventorship and of rights being given to third parties required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

0
17

Claim(s)

4

Abstract

1

Drawing(s)

13 + 13

10. If you are also filing any of the following, state how many against each item.

Priority documents

0

Translations of priority documents

0

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

3

Request for preliminary examination and search (Patents Form 9/77)

1

Request for substantive examination

0

(Patents Form 10/77)

Any other documents

0

(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date: 18/07/97

12. Name and daytime telephone number of person to contact in the United Kingdom

David Lethem

0171 404 0116

Hoffmann Eitle

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

18 JUL 1997 / 18 JUL 1997

Statement of inventorship and of right to grant of a patent

18 JUL 1997

RECEIVED BY HAND

1. Your reference

P12266 r6/tm

2. Patent application number

(if you know it)

9715214.4

18 JUL 1997

3. Full name of the or of each applicant

Finnfeeds International Ltd.

4. Title of the invention

USE OF AN ENZYME FOR MANUFACTURING AN AGENT FOR CONTROLLING BACTERIAL INFECTION

5. State how the applicant(s) derived the right from the inventor(s) to be granted a patent

By virtue of the first inventor's employment by Finnfeeds International Ltd and by virtue of an agreement dated 8 Jan. 1997 between Finnfeeds International Ltd and the University of Bristol to whom the second inventor is in turn under contract

6. How many, if any, additional Patents Forms 7/77 are attached to this form?

0

(see note (c))

7.

I/We believe that the person(s) named over the page (and on any extra copies of this form) is/are the inventor(s) of the invention which the above patent application relates to.

Signature

Date

18/07/97

8. Name and daytime telephone number of person to contact in the United Kingdom

David Lethem
Hoffmann · Eitle

0171 404 0116

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there are more than three inventors, please write the names and addresses of the other inventors on the back of another Patents Form 7/77 and attach it to this form.
- When an application does not declare any priority, or declares priority from an earlier UK application, you must provide enough copies of this form so that the Patent Office can send one to each inventor who is not an applicant.
- Once you have filled in the form you must remember to sign and date it.

except as otherwise agreed

18 JUL 1997 / 18 JUL 1997

THE PATENT OFFICE

THE PATENT OFFICE

Enter the full names, addresses and postcodes of the inventors in the boxes and underline the surnames

Surnames underlined for accuracy

Michael R. Bedford, Finnfeeds International Ltd.
Market House, Aylesbury Court
MARLBOROUGH, SN8 1AA
United Kingdom

6535504001

Patents ADP number (if you know it):

Mr Michael R. Bedford, Finnfeeds International Ltd.
Market House, Aylesbury Court, Marlborough, SN8 1AA
United Kingdom

Fresie Fernandez, Department of Animal Husbandry
University of Bristol
Langford House, LANGFORD,
BS18 7DU
United Kingdom

7253511001

Patents ADP number (if you know it):

Mr Fresie Fernandez, Department of Animal Husbandry
University of Bristol
Langford House, LANGFORD,
BS18 7DU
United Kingdom

RECENTLY NO DIFFERENTIALS ON THE FARM, BUT
NO INVENTOR'S NAME ON THE INVENTION FORM
DUE TO NO INVENTOR'S NAME ON THE INVENTION FORM

REMEMBER ALL INVENTORS ARE MENTIONED ON THE
Reminder

Have you signed the form?

RECENTLY NO DIFFERENTIALS ON THE FARM, BUT
NO INVENTOR'S NAME ON THE INVENTION FORM
DUE TO NO INVENTOR'S NAME ON THE INVENTION FORM

Patents ADP number (if you know it):

Finnfeeds International Ltd.

P12266 r6/tm

USE OF AN ENZYME FOR MANUFACTURING AN AGENT FOR
CONTROLLING BACTERIAL INFECTION

The present invention is directed to the use of an enzyme for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.

- 5 The farming of many different types of animals is important throughout the world for the production of food for human consumption. When the animals are reared, they come into contact with a variety of infection-causing bacteria, such as *Campylobacter* and
- 10 *Salmonella*. In some cases these bacteria may spread directly from animals to humans (zoonosis). Accordingly, it is necessary from an economic, environmental and health perspective that such bacterial infection is prevented or eradicated in the
- 15 animal prior to human consumption to prevent the spread of the disease to humans.

The domestic animal of particular, but not exclusive, concern with regard to zoonosis is the chicken.

Campylobacter and *Salmonella* are particularly prevalent in the chicken. The bacteria are transmitted to the bird in a variety of ways, including through feed, water, litter and vermin. The bacteria initially infect
5 the caecae of the chicken. The disease then progresses to the small intestine where infestation may cause loss of weight in the bird. A particular problem with the chicken is that it is almost impossible to eviscerate in a sterile manner with the result that bacteria
10 inhabiting the intestines will invariably be transmitted to the saleable carcass. Accordingly the potential for zoonosis is great, unless the carcass is handled or cooked properly. The cost of human infection caused by eating improperly treated chicken is
15 significant in terms of both time and lives.

Accordingly, presently there is a demand for improved methods of reducing bacterial infection in animals such as the chicken, in particular those intended for human
20 consumption.

Various solutions to the problem of bacterial infection have been proposed. Current methods of control include the application of antibiotics, feed sterilisation and
25 careful and controlled handling and cooking of the carcass after slaughter. Feed sterilisation has proved ineffective in the absence of a sterile rearing environment (which is impractical) whilst controlled

handling and cooking cannot be relied upon in every instance. The application of antibiotics has proved unpopular with consumer groups wishing to reduce the quantity of potentially harmful chemicals in food. The
5 use of antibiotics has the additional problem that if they are not introduced into the animal in a properly controlled manner, antibiotic-resistant strains of bacteria can be created, making such infections more difficult to treat in the future. The prophylactic use
10 of antibiotics in animal feed has thus been regulated in some countries (notably Sweden and Finland) effectively reducing the available methods of control. Indeed no single method provides a barrier which completely prevents bacteria being transferred from the
15 animal to humans.

As an alternative to the above methods it has been proposed in *Poultry Science*, 1994 73:402-407, to introduce flora into chickens to compete with the
20 bacteria causing the infection. Such mucosal competitive exclusion flora (MCE) were found to reduce the level of *Campylobacter jejuni* infection in chickens. However, the competitive exclusion treatment is not found to be consistently effective, its efficacy
25 varying from animal to animal.

JP-A-81-73055 discloses animal feeds intended to prevent contamination with *Salmonella*. The feeds are indicated to contain partially decomposed mannan in the

form of mannose polysaccharides. These are produced by degradation of mannan with an enzyme, produced by micro-organisms. The resulting feed was found to be moderately effective against *Salmonella* in chickens,
5 but is not effective against *Campylobacter*.

US-A-5 124 262 discloses a mannose isomerase enzyme used for converting fructose to mannose. The mannose thus produced is taught to be useful in feeds, for
10 inhibiting the growth of *Salmonella* in chickens.

In Bamboo J. 1993, pp. 29-35, xylan prepared from steamed bamboo grass is mentioned as inhibiting the growth of various human intestinal bacteria. In
15 particular the xylan is indicated to be effective against *Salmonella*. However, the inhibition effect is reversed after a period of 24 hours.

The above methods have proved more desirable from an
20 environmental and health point of view, than the administration of antibiotics. However, none have proved effective enough to be commercially viable.

WO 93/01800 discloses the use of a protease for the
25 preparation of a medicament effective against intestinal pathogens in animals. The pathogens of interest include *Campylobacter*. However, there is no mention of enzymes other than proteases being useful in controlling animal pathogens.

EP-A-0 681 787 discloses use of a carbohydrase or protease for the manufacture of an agent for the treatment of *Coccidiosis*. However, *Coccidiosis* in chickens is caused by protozoal oocytes. The document does not indicate how bacterial pathogens in chickens, or other animals, can be controlled.

Accordingly, one object of the present invention is to provide an agent which can be used for controlling bacterial infection that is more effective than the presently available agents, and in particular than those described in the prior art acknowledged above. A further object of the present invention is to provide an agent which can be used for controlling bacterial infection that is less harmful to the environment, less expensive than the presently available agents, and has advantages for human health.

Accordingly, the present invention provides the use of a carbohydrase in the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.

Figure 1 shows the effect of three diets on *Campylobacter* colonisation in 12-day old chicks. Three different dilution levels of the initial stock solution of *Campylobacter* were used to introduce the pathogen to the chicks. The results are presented as mean scores of positive caecae and represent the combined results of

two flocks A and B comprising a total of 108 birds (12 per dilution for each of the three diets).

Figure 2 shows the results of Figure 1, but for flock A
5 alone.

Figure 3 shows the results of Figure 1, but for flock B
alone.

10 Figure 4 shows similar results to Figure 1, but at three alternative dilution levels of the initial *Campylobacter* stock solution. The results are presented as mean counts \log_{10} CFU(Colony Forming Units)/ml.

15 Figure 5 shows the results of Figure 4, but for flock A
alone.

Figure 6 shows the results of Figure 4, but for flock B
alone.

20 Figure 7 shows the effect of three diets on *Campylobacter* colonisation of the small intestine and caecae of 17-day old chicks. The results are presented as mean counts \log_{10} CFU/ml, and represent the combined
25 results of two flocks A and B comprising a total of 72 birds (12 per treatment) for each of the three diets.

Figure 8 shows the results of Figure 7, but for flock A
30 alone.

Figure 9 shows the results of Figure 7, but for flock B alone.

Figure 10 shows a comparison of the weight of 1, 5, 12,
5 19, 25 and 33-day old chicks (20 in total) dosed with
Campylobacter jejuni, and similar chicks (25 in total)
which have not been dosed, the chicks all being fed a
wheat-based diet.

10 Figure 11 shows similar results to those of Figure 10,
but for chicks on a wheat plus xylanase diet.

Figure 12 shows similar results to those of Figure 10,
but for chicks on a maize-based diet.

15 Figure 13 shows the effect of two different diets
(wheat and wheat plus xylanase) on *Salmonella*
enteritidis colonisation in 14 day old chicks. The
results are presented as mean counts \log_{10} CFU/ml. Tests
20 were carried out on two flocks, A and B, comprising a
total of 48 birds, 24 per diet.

The advantage of using feeds containing carbohydrase
for rearing animals is that the amount of antimicrobial
25 drugs which have previously been routinely incorporated
into their diet can be reduced, or in some cases
omitted entirely. This enables considerable economic
savings to be achieved in view of the relative expense
of antibiotics. In countries where such drugs are

banned, it represents a totally new alternative for the control of diseases.

When omitting antibiotics from an animal's diet there
5 are several potential further benefits. It has previously been necessary to withdraw antibiotics from the animal's diet for a certain time prior to slaughter. This ensures that the meat is relatively free from such drugs and thus fit for human
10 consumption. In contrast, if antibiotics are entirely omitted from an animal's diet, as may be achieved with the present invention, then the animal can be slaughtered at any age rather than after a certain withdrawal period. This affords the farmer improved
15 flexibility and removes the risk of animals becoming infected shortly prior to slaughter. Further, meat and eggs can be guaranteed free of antibiotics. Such meat and eggs have a market advantage as compared to products which cannot support such a guarantee.

20

Even if the enzyme added to the animal's diet only enables the level of inclusion of antibiotics to be reduced, then the overall cost of controlling bacterial infection will be reduced. Synergy or potentiation may
25 extend the useful life of the antibiotic.

The present invention also has benefits for human health. Its use reduces the selection pressure for antibiotic-resistant strains of bacteria, by allowing

antibiotics to be removed from animal feed. Accordingly, more antibiotic-susceptible strains will be present in the gut of the animal, thereby ensuring a more likely positive outcome in the event of 5 antibiotics being used on the equivalent human condition.

The enzyme to be used in the feeds can be formulated as a pre-mix together with any other enzymes to be 10 included. The pre-mix can be added to the raw materials before feed manufacture, during feed manufacture or as a final step once the feed is otherwise ready for use. It is possible to add the enzyme directly as a liquid to a feed material pre-formed as pellets or as a mash.

15

It is also possible to include the enzyme in the animal's diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that 20 the enzyme is incorporated into the feed itself, although such incorporation forms a particularly preferred aspect of the present invention.

If the enzyme is incorporated into a feed, then this 25 preferably comprises at least 25% by weight of a cereal, and more preferably at least 35% by weight of the cereal. The cereal may be any one or more of wheat, maize, rye, barley, oats, triticale, rice, and sorghum. It is particularly preferred that the cereal is wheat.

Although the cereal component of a cereal-based diet constitutes a source of protein, it is usually necessary to include sources of supplementary protein 5 in the diet, such as those derived from fishmeal, meatmeal or vegetables. These sources of supplementary protein may constitute up to 50% by weight of the animal feed. Sources of vegetable protein include at least one of full fat soybean, rapeseed, canola, 10 soybean meal, rapeseed meal and canola meal.

If the enzyme is incorporated into a feed, then this is preferably added in a relative amount of 0.0001-10 g of the enzyme per kilo of the feed, more preferably 15 0.001-1 g/kg and most preferably 0.01-0.1 g/kg.

The carbohydrase, is preferably a polysaccharidase such as a xylanase, a cellulase, an α -amylase, a pectinase or a pentosanase. A preferred cellulase is β -glucanase.

20

If the polysaccharidase is a xylanase, then this can be obtained from a fungus, such as *Trichoderma*, *Aspergillus*, *Humicola*, or *Neocallimastix*. Alternatively, xylanase can also be obtained from a 25 bacterium, such as *Bacillus*, *Streptomyces*, *Clostridium*, or *Ruminococcus*.

The present invention can be used effectively against a wide variety of bacteria. It is particularly effective

against strains of *Salmonella* and *Campylobacter*, and especially *Salmonella enteritidis* and *Campylobacter jejuni*. Another bacterium against which the invention is effective is *Clostridium perfringens*.

5

Bacterial infection can be treated or prevented in accordance with the present invention in a wide variety of animals, but use of the invention is particularly preferred in domestic animals and farm livestock.

10 Animals which may in particular benefit from the invention include poultry (such as chickens, turkeys, ducks and geese), ruminants (such as cattle, horses and sheep), swine (pigs), cats, dogs, rodents (such as rabbits) and fish. The invention is particularly useful
15 in broiler chickens.

The most preferred combinations of feed and enzyme include wheat plus xylanase, maize plus xylanase and barley plus β -glucanase.

20

The carbohydrase enzymes used in the present invention are broadly classed as polysaccharidases. Their substrates are structural polysaccharides such as xylans and β -glucans that occur as an integral part of
25 the cell wall of most land plants. These polysaccharides are not found in animal cells, and are not to be expected to have any activity against proteins. Because these enzymes attack polysaccharides found in plant cell walls, the only possible substrates

for these enzymes in the gastrointestinal tract of an animal are contained in cereal-based feeds. It is therefore speculated that the beneficial effects of the carbohydrases on bacterial infection result somehow 5 from the degradation products of carbohydrases such as xylan or β -glucan contained in a cereal-based diet.

As previously mentioned, WO 93/01800 discloses the use of a protease for the preparation of a medicament 10 effective against intestinal pathogens in animals. It is well established that such pathogens mediate their infectivity by binding to receptors on the surface of intestinal epithelial cells via antigenic protein or glycoprotein molecules expressed on the pathogen's cell 15 surface. It is suggested that the protease enzyme prevents binding of the pathogen cells to the intestinal epithelium by destroying these proteinaceous receptor/adhesion sites to which the pathogen must bind if it is to cause an infection. The protease enzymes 20 mentioned in this reference would be predicted to destroy proteins on the luminal surface of intestinal epithelial cells in a non-specific manner, but would not be expected to attack substrates other than proteins. Accordingly, the activity of the proteases 25 disclosed in this reference is fundamentally different from the activity of the carbohydrase enzymes used in the present invention. A skilled person could not possibly have predicted the utility of the present

carbohydrase enzymes against bacterial infection based upon the activity of proteases disclosed in WO 93/01800.

5 The invention will now be described in more detail according to the following Examples.

Examples

10 General Methodology

Wheat and maize diets were prepared having the following formulations:

15 Table 1 - Wheat diet

Ingredients	Percent
Soft Wheat	58.83
Soybean ml 48	32.49
Soy oil	4.49
Salt	0.30
Sodium Bicarbonate	0.12
DL Methionine	0.14
Limestone	1.37
Di-calcium Phosphate	1.26
Vitamins/Minerals	1.00
TOTAL	100.00

Table 2 - Maize diet

Ingredients	Percent
Maize	55.38
Soybean ml 48	37.30
Soy oil	2.96
Salt	0.30
Sodium Bicarbonate	0.16
DL Methionine	0.13
Limestone	1.22
Di-calcium Phosphate	1.55
Vitamins/Minerals	1.00
TOTAL	100.00

Animal feeds were prepared by introducing a cereal carrier containing approximately 3 mg enzyme protein/kg 5 into the wheat diet at a concentration of 1 kg of enzyme and carrier per tonne of wheat diet. The final concentration of enzyme protein in the feed was thus approximately 3 mg per tonne. The xylanase was obtained from *Trichoderma longibrachiatum*. Broiler chicks were 10 fed the wheat plus xylanase diet from hatching. For comparison purposes, separate flocks of chicks were fed with the wheat diet and the maize diet without the addition of xylanase. A challenge model was used, whereby 0.2 ml of a stock solution of *C. jejuni* were 15 introduced to each chick by syringe at day 7 from hatching. The dilution level of the stock solution was varied, from 10^{-1} (high challenge) to 10^{-6} (low

challenge, similar to natural conditions). The undiluted stock solution contained approximately 10^4 CFU per 0.2 ml. The caecae of the chicks were examined for damage due to the *Campylobacter* at varying 5 ages.

Example 1

Figures 1-6 show the effect of the diets on 10 *Campylobacter* colonisation in 12-day old chicks. In each case two flocks, A and B, were tested to minimise the effect of environmental variance on the results. In each case it is clearly evident that a wheat plus xylanase diet is effective in reducing the level of 15 *Campylobacter* in the caecae of the chicks in comparison with a maize diet. Additionally, at *Campylobacter* stock solution dilution levels of 10^{-3} or lower (i.e. approaching more natural conditions), the wheat plus xylanase diet becomes considerably more effective than 20 the wheat diet alone. Thus, in Figure 1, for the wheat plus xylanase diet at a *Campylobacter* stock solution dilution of 10^{-6} , a mean score of 0.5 positive caecae was observed. The equivalent scores for diets lacking xylanase were approximately 1.5 and 2.5.

25

Example 2

Figures 7-9 demonstrate the effectiveness of the diets on 30 *Campylobacter* colonisation of the small intestine and caecae of 17-day old chicks from two flocks. The

effect of the wheat plus xylanase diet on reducing the *Campylobacter* colonisation of the caecae of the chicks is evident as already demonstrated in Example 1. However this reduction is even more marked as regards
5 the small intestine. Accordingly, in Figure 7 the mean count \log_{10} CFU in the small intestine measured for chicks on the wheat and xylanase diet was less than 4. The equivalent counts for the diets not containing xylanase were found to be approximately 6, i.e.
10 100-fold higher.

Example 3

Figures 10-12 depict a comparison of the effect of
15 different diets on the weight of 1, 5, 12, 19, 25 and 33-day old chicks. Figure 10 shows the results for the wheat-based diet, Figure 11 the results for the wheat plus xylanase-based diet and Figure 12 the results for the maize-based diet. The weight of the chicks in each
20 case is reduced by dosing with *Campylobacter*. However, those chicks to which *Campylobacter* has been introduced gain weight more quickly on the wheat plus xylanase diet than on either of the other diets.

25 **Example 4**

Figure 13 demonstrates the effectiveness of the wheat and wheat plus xylanase diets on *Salmonella enteritidis* colonisation of the caecae of 14-day old chicks from
30 two flocks, A and B. The methodology employed in these experiments was identical to that employed for the

Campylobacter experiments described above, except that the undiluted stock solution of *Salmonella enteritidis* contained approximately 10^5 CFU per 0.2 ml. The effect of the wheat plus xylanase diet on reducing the 5 *Salmonella* colonisation of the caecae of the chicks is clearly evident. Thus, in flock B, the chicks on the wheat diet were found to have a mean count \log_{10} CFU/ml of approximately 7. However, the chicks from flock B on the wheat plus xylanase diet were found to have a much 10 lower \log_{10} CFU/ml of approximately 4 (1000-fold lower).

The Examples clearly show a reduction in bacterial infection in the gut due to the use of carbohydrase in the diet. This indicates that the use provided by the 15 present invention significantly reduces the ability of bacteria to colonise the caecae which in turn prevents migration of the bacteria to the small intestine. Accordingly, since it has a reduced level of infection, the growth rate of the animal is increased, leading to 20 economic benefits. The reduction in contamination rate also has obvious benefits to human health and the replacement of antibiotics by such diets has clear environmental benefits. The invention and its advantages could not have been predicted on the basis 25 of the prior art.

Finnfeeds International Ltd.

P12266 r6/tm

Claims:

1. Use of a carbohydrase for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.
- 5 2. Use according to Claim 1, wherein the agent is in the form of an animal feed.
3. Use according to Claim 2, wherein the agent comprises at least 25% of a cereal.
- 10 4. Use according to Claim 3, wherein the agent comprises at least 35% of a cereal.
5. Use according to Claim 3 or Claim 4, wherein the cereal is wheat, maize, rye, barley, oats, triticale, rice and/or sorghum.
- 15 6. Use according to Claim 5, wherein the cereal is wheat.
- 20 7. Use according to any of Claims 2-6, wherein the agent further comprises a supplemental source of protein.

8. Use according to Claim 7, wherein the supplemental source of protein is fishmeal, meatmeal or a vegetable protein.

5

9. Use according to Claim 8, wherein the vegetable protein is full fat soybeans, rapeseed, canola, soybean meal, rapeseed meal and/or canola meal.

10 10. Use according to any of Claims 2-9, wherein the animal feed comprises 0.0001-10 g/kg of the enzyme.

11. Use according to Claim 10, wherein the animal feed 15 comprises 0.001-1 g/kg of the enzyme.

12. Use according to Claim 11, wherein the animal feed comprises 0.01-0.1 g/kg of the enzyme.

20 13. Use according to any preceding Claim, wherein the carbohydrase is one or more polysaccharidases.

14. Use according to Claim 13, wherein the polysaccharidase is a xylanase.

25

15. Use according to Claim 14, wherein the xylanase is obtained from a fungus.

16. Use according to Claim 15, wherein the fungus is *Trichoderma*, *Aspergillus*, *Humicola* or *Neocallimastix*.

5 17. Use according to Claim 14, wherein the xylanase is obtained from a bacterium.

10 18. Use according to Claim 17, wherein the bacterium is *Bacillus*, *Streptomyces*, *Clostridium*, or *Ruminococcus*.

19. Use according to Claim 13, wherein the polysaccharidase is a cellulase.

15 20. Use according to Claim 19, wherein the cellulase is a β -glucanase.

20 21. Use according to Claim 13, wherein the polysaccharidase is an α -amylase, a pectinase or a pentosanase.

22. Use according to any preceding Claim, wherein the bacterium causing the infection is *Salmonella enteritidis*, *Campylobacter jejuni* and/or *Clostridium perfringens*.

25 23. Use according to any preceding Claim, wherein the agent is adapted to be administered to livestock,

selected from poultry, ruminants, swine, cats,
dogs, rodents and fish.

24. Use according to Claim 23, wherein the livestock
5 is a broiler chicken.

25. Use of a carbohydrase for the manufacture of an
agent for the treatment or prophylaxis of a
bacterial infection, as substantially hereinbefore
10 described in any of the Examples.

ABSTRACT

USE OF AN ENZYME FOR MANUFACTURING AN AGENT FOR
CONTROLLING BACTERIAL INFECTION

Provided is the use of a carbohydrase for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.

- 5 It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective in controlling *Campylobacter* and *Salmonella* in chickens.
- 10 The use provided by the present invention affords an alternative to antibiotics when controlling bacterial infection in animals. This leads to considerable health, environmental and economic benefits.

FIG.1






FIG.2.






FIG.3




FIG.4






FIG.5







FIG. 6





7/13

FIG 7




FIG 8








FIG 9





10/13


FIG.10





11/13

FIG.11





12/13

FIG.12






Fig. 13

